ATB-346 (Synonyms: ATB-346) |
| Catalog No.GC18133 |
ATB-346 (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1226895-20-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ATB-346 is a hydrogen sulphide-releasing anti-inflammatory drug [1].
ATB-346 is a non-steroidal anti-inflammatory drug (NSAID) and shows a markedly reduced toxicity than its parent compound naproxen. In the airpouch model, ATB-346 significantly inhibited the PGE2 level and completely suppressed the whole blood TXB2 synthesis without causing gastric damage. In rats with adjuvant-Induced arthritis, administration of ATB-346 reduced the paw volume on days 14 and 21 notably. ATB-346 did not exert any damage or bleeding in the stomach or small intestine while naproxen caused bleeding in the small intestine. Besides that, administration of naproxen twice daily for 5 days in rats resulted in extensive damage in the small intestine. In contrast, same dose of ATB-346 caused quite little damage over the treatment of the 5 days [1].
References:
[1] Wallace J L, Caliendo G, Santagada V, et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). British journal of pharmacology, 2010, 159(6): 1236-1246.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *